With 90% of assets entering clinical trials failing to reach the market and R&D costs continuing to rise, it is more important than ever for pharmaceutical companies to understand the value of their portfolios. High failure rates make the cost of every drug more expensive, and the majority of R&D costs can be attributed to those that fail. It’s becoming more and more critical for pharmaceutical companies to find a path to better predictions.
With the seamless integration of Drug Timeline & Success Rates with the broader Cortellis suite, you can generate forecasts and gain a better understanding of the market based on gold-standard drug development, clinical, regulatory and deals data. Find out more from this report!